A randomized trial of 24- vs. 48-week courses of PEG interferon α-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients:: a pilot study in Taiwan

被引:37
作者
Yu, ML
Dai, CY
Lin, ZY
Lee, LP
Hou, NJ
Hsieh, MY
Chen, SC
Hsieh, MY
Wang, LY
Chang, WY
Chuang, WL
机构
[1] Kaohsiung Med Univ, Coll Med, Fac Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Chung Ho Mem Hosp, Dept Internal Med, Hepatobiliary Div, Kaohsiung, Taiwan
[3] Kaohsiung Municipal Hsiao Kang Hosp, Dept Occupat Med, Kaohsiung, Taiwan
关键词
duration; fibrosis; HCV; PEG interferon; ribavirin; viral load;
D O I
10.1111/j.1478-3231.2005.01196.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: To assess the efficacy of 24- or 48-week peginterferon/ribavirin treatment of Taiwanese patients with chronic hepatitis C virus genotype-1b (HCV-1b) infection, and to identify subgroups of patients in whom the 48-week treatment has benefits. Methods: We assigned 60 patients receiving peginterferon-alpha-2b (80-100 mcg/week) plus ribavirin (1000-1200 mg/day), depending on body weight, for 24 or 48 weeks, with a 3:1 randomization ratio. Results: The sustained virological response (SVR) rate was significantly higher in the 48-week (80.0%, 12/15) than in the 24-week group (48.9%, 22/45, P<0.05). The 60 patients were classified into two subgroups according to the presence of unfavorable baseline predictors: viral loads >= 400 000 IU/ml or a hepatic fibrosis score of 3-4. In 19 patients without an unfavorable predictor, the SVR rate was comparable in the 24-week (78.6%) and 48-week (75.0%) groups; in patients with either unfavorable predictors, the SVR rate was significantly higher in the 48-week (81.1%, 9/11) than in the 24-week group (36.7%, 11/30, P=0.0 15). The discontinuation rate was significantly higher in the 48-week (20.0%, 3/15) than in the 24-week group (2.2%, 1/45, P<0.05). Conclusion: A 48-week course of peginterferon-alpha-2b/ribavirin was more effective than a 24-week course in Taiwanese HCV-1b patients, mainly in those with high viral loads and/or advanced hepatic fibrosis.
引用
收藏
页码:73 / 81
页数:9
相关论文
共 29 条
[1]  
[Anonymous], 1999, J Hepatol, V31 Suppl 1, P3
[2]  
Cappiello G, 2003, ANTIVIR THER, V8, P105
[3]   Treatment of chronic hepatitis C in southern Taiwan [J].
Chuang, WL ;
Yu, ML ;
Dai, CY ;
Chang, WY .
INTERVIROLOGY, 2005, 49 (1-2) :99-106
[4]   Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C [J].
Davis, GL ;
Wong, JB ;
McHutchison, JG ;
Manns, MP ;
Harvey, J ;
Albrecht, J .
HEPATOLOGY, 2003, 38 (03) :645-652
[5]   A 48-week duration of therapy with pegylated interferon α2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus [J].
Drusano, GL ;
Preston, SL .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) :964-970
[6]   COMPARISON OF FULL-LENGTH SEQUENCES OF INTERFERON-SENSITIVE AND RESISTANT HEPATITIS-C VIRUS 1B - SENSITIVITY TO INTERFERON IS CONFERRED BY AMINO-ACID SUBSTITUTIONS IN THE NS5A REGION [J].
ENOMOTO, N ;
SAKUMA, I ;
ASAHINA, Y ;
KUROSAKI, M ;
MURAKAMI, T ;
YAMAMOTO, C ;
IZUMI, N ;
MARUMO, F ;
SATO, C .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :224-230
[7]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[8]   Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].
Hadziyannis, SJ ;
Sette, H ;
Morgan, TR ;
Balan, V ;
Diago, M ;
Marcellin, P ;
Ramadori, G ;
Bodenheimer, H ;
Bernstein, D ;
Rizzetto, M ;
Zeuzem, S ;
Pockros, PJ ;
Lin, A ;
Ackrill, AM .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355
[9]   Prevention of hepatitis C virus-related hepatocellular carcinoma [J].
Heathcote, EJ .
GASTROENTEROLOGY, 2004, 127 (05) :S294-S302
[10]   Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin [J].
Hung, CH ;
Lee, CM ;
Lu, SN ;
Lee, JF ;
Wang, JH ;
Tung, HD ;
Chen, TM ;
Hu, TH ;
Chen, WJ ;
Changchien, CS .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (02) :87-94